Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

The purpose of the study is to evaluate whether hCG will result in a decrease in breast density.

High breast density has been associated with an increased risk in breast cancer. It has also been shown that decreasing density with a drug called tamoxifen has resulted in a decreased risk in breast cancer. The investigators are looking at the effect of hCG on breast density in people who are at increased risk of developing breast cancer and our theory postulates that through the hormonal actions of hCG and tamoxifen there would be a greater reduction in breast density in patients who are treated with hCG and tamoxifen versus patients treated with tamoxifen alone. Using this data the investigators will be able to hypothesize that the treatment of hCG will result in a reduction in breast cancer rates in the population and thus make available another drug which can be used to decrease the rates of breast cancer in the population

Further Study Information

Pregnancy has been associated with a decreased risk of breast cancer. This has been reproduced in multiple studies and has been seen in multiple races.

People have been evaluating different hormones and practices associated with pregnancy to determine what factors reduce the risk of developing breast cancer in these patients. These pronounced findings have been evaluated in great detail by multiple scientists and one of the hormones which we think might be associated with a reduction in breast cancer is hCG. This statement has been backed by multiple studies which have looked at the direct effect of hCG on the growth and death of breast cancer cells in the lab and in animal models of breast cancer.

We want to determine if hCG is given to patients who are at increased risk of breast cancer will result in an accentuated decrease in breast cancer risk above and beyond the effect received by conventional breast cancer reducing protocols. Our final outcome in this study will be breast density on mammographic evaluation which is considered a marker for breast cancer. So our study will evaluate whether or not hCG will have an effect on the mammographic breast density.

After recruitment there will be two groups in our study an intervention group and non intervention group. In the intervention group patients would undergo a period of hCG injections which would last a total of 60 days and consist of 30 subcutaneous injections. The non intervention group will continue their conventional chemoprevention medication. Both groups will be followed for teo years and the images, cytology and blood samples will be sent to our labs for evaluation.

Eligibility Criteria

Inclusion Criteria:

• On tamoxifen therapy for the treatment or prevention of breast cancer.

• Must have at least one remaining breast.

Exclusion Criteria:

• Pregnant or nursing.

• No history of allergic reactions to hCG.

• Patients who have had bilateral mastectomies.

• Uncontrolled thyroid disease.

• Cognitively impaired and unable to consent for the trial.

Trial Contact Information

Trial Lead Organizations/Sponsors

NYU Downtown Hospital

U.S.A.
New York
	New York
	NYU Cancer Institute at New York University Medical Center
		Giuseppe Del Priore, MD, MPH	Ph: 212-312-5268
			Email: nydresearch@downtownhospital.org
		Alan S Klapper, MD	Sub-Investigator
		Steven Freidman, MD	Sub-Investigator
		Joseph C. Bottino	Sub-Investigator
		Raffi Chalian, MD	Sub-Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00808522
Information obtained from ClinicalTrials.gov on December 14, 2011

Back to Top